Business Wire

GEMALTO

Share
Gemalto Expands Cloud HSM On Demand Solutions

Gemalto, the world leader in digital security, today announced the availability of three new cloud-based Hardware Security Module (HSM) services, HSM On Demand for CyberArk , HSM On Demand for Hyperledger and HSM On Demand for Oracle TDE . Each service is available through the SafeNet Data Protection on Demand platform, a marketplace of cloud-based HSM, encryption and key management services that easily integrates with most widely used cloud services and IT products to protect data wherever it is created, accessed or stored.

The rapid adoption of cloud and digital services has made it difficult for organizations to secure data and identities that are created, stored and managed outside the perimeter. While organizations recognize that data encryption is the optimal solution to secure sensitive information, they can be challenged by the cost and complexity of deploying encryption, including Hardware Security Modules to secure their cryptographic operations. Gemalto’s SafeNet Data Protection On Demand solves these challenges by providing cloud-based HSM services that and can be deployed in minutes without the need for highly skilled staff. Gemalto, a leader in the HSM market, is proven to help customers secure their encryption keys and data across cloud, hybrid, and on-premises environments.

“A worsening threat landscape, combined with aggressive cloud adoption and evolving privacy regulations, have presented complex new challenges related to encryption, privileged access and financial transactions,” said Todd Moore, Senior Vice President of Encryption Products at Gemalto. “Our newest Cloud HSM On Demand services help organizations stay in front of new threats and regulations, by easily deploying an HSM solution for the strongest possible key management and security practices, all while providing fast, easy set-up, with remarkable savings over traditional approaches involving specialized hardware and skills.”

“Many organizations would like to deploy data security more broadly, but are often wary due to concerns about complexity, cost and staffing requirements, particularly with respect to encryption and key management,” said Garrett Bekker, Principal Analyst at 451 Research. “The release of SafeNet Data Protection On Demand was a positive step towards addressing those concerns, and extending its cloud HSM capability to newer use cases like blockchain, database security and privileged credentials is a logical and timely move.”

HSM On Demand for CyberArk
HSM On Demand for CyberArk works seamlessly with CyberArk’s Privileged Access Security Solution, providing private key protection and strong entropy for key generation for system keys.. By securing the master key and ensuring that it is hosted in a secure vault, HSM On Demand for CyberArk mitigates the risk of the master key being exposed or compromised.

HSM On Demand for Hyperledger
HSM On Demand for Hyperledger provides trust for blockchain transactions by securing the cryptographic keys that sign them. It protects digital wallets, while ensuring keys are readily available in the cloud once access is granted. The service provides high assurance security in data centers and the cloud, enabling multi-tenancy of blockchain identities per partition as proof of transaction and for auditing requirements. It also delivers performance improvements resulting from off-loading cryptographic operations from application servers to the HSM on Demand service.

HSM On Demand for Oracle TDE
HSM for Oracle TDE (Transparent Data Encryption) solves the challenge presented by locally stored encryption keys by protecting them with a master key, stored in a separate service key vault. This ensures that only authorized services are allowed to request the local key to be decrypted. If an attacker steals the database, it is encrypted and inaccessible, since the attacker does not have access to the keys that are securely stored on the HSM.

Additional Resources

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security , with 2018 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.

From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.

Our 15,000 employees operate out of 110 offices, 47 personalization and data centers, and 35 research and software development centers located in 47 countries.

For more information visit www.gemalto.com , or follow @gemalto on Twitter.

Contact:

Gemalto media contacts: Tauri Cox North America +1 512 257 3916 tauri.cox@gemalto.com

Sophie Dombres Europe Middle East & Africa +33 4 42 36 57 38 sophie.dombres@gemalto.com

Jaslin Huang Asia Pacific +65 6317 3005 jaslin.huang@gemalto.com

Alexis Camarillo Latin America +52 5521223627 alexis.camarillo@gemalto.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye